Table 2. Association between PD-L1 expression and clinicopathological characteristics.
| Clinicopathological feature | Studies | Heterogeneity | OR (95% CI) | P-value | |
|---|---|---|---|---|---|
| P-value | I2 (%) | ||||
| Sex | 11 | 0.60 | 0 | 0.92 (0.73–1.16) | 0.48 |
| Differentiation | 9 | 0.002 | 68 | 1.01 (0.66–1.54) | 0.95 |
| T stage | 6 | 0.02 | 64 | 0.96 (0.60–1.53) | 0.86 |
| N stage | 9 | < 0.00001 | 79 | 1.26 (0.80–2.00) | 0.31 |
| Metastasis | 4 | 0.97 | 0 | 1.58 (1.03–2.42) | 0.04 |
| TNM stage | 8 | 0.02 | 57 | 0.99 (0.72–1.38) | 0.97 |
| Lymphatic invasion | 3 | 0.20 | 37 | 1.15 (0.81–1.65) | 0.44 |
| Venous invasion | 3 | 0.22 | 34 | 1.06 (0.67–1.67) | 0.80 |
| Neoadjuvant treatment | 3 | 0.04 | 70 | 1.28 (0.57–2.92) | 0.55 |
| Drinking | 2 | 0.30 | 5 | 0.89 (0.63–1.27) | 0.53 |
| Smoking | 3 | 0.65 | 0 | 0.86 (0.64–1.14) | 0.30 |